ONUMMIX® is focused to explore the role of biomarkers in immunogenomics. Our interests in immunogenomics research include the evaluation of multiple biomarkers, to design a composite biomarker approach and the creation of computational methods for predicting antigen presentation and TCR binding.
The field of immunogenomics broadly combines the genomics of tumour cells and immune cells, in an attempt to understand the mechanism of immune response towards cancer.
KNOW MORE ABOUT BIOMARKERS
Immunotherapy mediated change in the immune cell selection, and their selectivity (and associate pressure) towards cancer cells.
How do the tumour cells adapt themselves to survive the growing pressure?
How does a tumour escape anti-tumour immunity?
How to improve the effectiveness of immunotherapy in all patients, with minimisation of risks.
Cancer is a complex disease in terms of the aberrant behaviour of cancer cells and the hijacking of functioning of the tissues and organs that they attack. Our body’s defence comprising of the immune system is equally complex and relies on specific mechanisms to distinguish a healthy normal cell from a cancer cell within the body, and eliminate the latter. The immune system always stays on alert and eliminates cancer cells automatically without our knowledge, thus preventing the progression of cancer or the growth of tumour. However, diagnostic detection of a tumour implies that our internal immune system has failed to achieve its target.
Immunotherapy relies on multimodal approach based on the use of diverse biological agents that boost the immune response of the body. The goal of immunotherapy is to create a specialised army of immune cells that are experts not only in identifying cancer but also eliminating them. Research suggests that immunotherapy has achieved success in certain types of cancers only, and also in certain population of patients, thus limiting its generalizability.
Referred to as a disease of the genome, cancer is one of the highly studied conditions of the present times. Though many factors play a role in the onset and progression of cancer, the role of genetics is considered to be the strongest.
Immunogenomics, combines the fields of immunology and genomics in developing enhanced immune responses for conditions like cancer. At present, this science has developed based on the existing sequencing techniques, along with microarrays, mass spectrometry, NMR, chromatography, PCR, mass cytometry, data repositories, experimental designs, and statistical methods.